Physician profile
Cody Shinavier
NPI 1952878092
$40,833.54
in general payments reported to CMS, 2019-2025
24 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $2,242 · 2023: $2,956 · 2024: $3,195 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $18K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,618 · Travel and Lodging: $2,011 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $17,600.00 |
| Food and Beverage | $11,332.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,618.00 |
| Travel and Lodging | $2,010.78 |
| Education | $193.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21,186.72 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $7,866.83 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,854.44 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,654.71 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,028.05 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,015.39 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,000.57 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $795.14 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $645.34 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $619.23 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $593.13 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $532.02 | 2021-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $451.87 | 2022-2025 | Auvelity |
| Lundbeck LLC | $383.92 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $353.36 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $305.50 | 2025 | Jornay Pm |
| Indivior INC. | $159.09 | 2022-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $129.83 | 2022-2023 | Quviviq |
| Noven Therapeutics, LLC | $88.14 | 2024-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $63.81 | 2021-2022 | |
| Tempus Ai, INC | $48.70 | 2024 | |
| Almatica Pharma LLC | $25.03 | 2023 | Loreev Xr, Sertraline Hcl |
| Biogen, INC. | $21.19 | 2024 | |
| Brainsway USA INC | $11.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Shinavier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.